IDEAYA Biosciences Names Stu Dorman As New Chief Commercial Officer

IDEAYA Biosciences, Inc., a company focused on precision medicine in oncology, has announced the appointment of Stu Dorman as its new Chief Commercial Officer. With more than 20 years of experience in oncology and hematology, Mr. Dorman brings a strong record of success in commercializing treatments across various specialty disease areas.

Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences, said in a statement, “We are thrilled to welcome Stu as IDEAYA makes continued enrollment progress in the potential registrational trial for darovasertib in first-line HLA-A2(-) MUM, and the potential indication expansion opportunity in neoadjuvant UM. Stu has extensive commercial experience in global product commercialization, product launches, sales and market access. Most importantly, Stu's proven track record in maximizing the commercial opportunity for several global blockbuster cancer treatments, such as Trodelvy® and Opdivo®, makes him an ideal fit to lead our commercial organization,"

Before joining IDEAYA, Mr. Dorman served as Vice President and U.S. Oncology Business Unit Head at Gilead Sciences, where he played a key role in building a top-tier oncology commercial organization with over $1 billion in global annual sales. He was also instrumental in the successful launch of Trodelvy across multiple indications. 

"I am delighted to join IDEAYA to build an industry-leading commercial organization that is well positioned to deliver potential first-in-class precision medicine oncology therapies that can improve the lives of cancer patients worldwide. I look forward to leveraging my extensive commercial oncology experience as darovasertib continues to make progress in the potential registrational trial in first-line HLA-A2(-) MUM and targeted Phase 3 start in neoadjuvant UM, and as the broader clinical pipeline advances, including IDE397 in MTAP-deletion non-small cell lung cancer and urothelial cancer," stated Mr. Dorman.

Earlier in his career, Mr. Dorman held several senior roles at Bristol Myers Squibb (BMS), where he led and transformed global sales and marketing teams, achieving exceptional commercial success, including the launch of key oncology treatments like Opdivo, Yervoy, and Abraxane. He concluded his 14-year career at BMS as Vice President of Worldwide Oncology Commercialization. Mr. Dorman earned his M.B.A. from Stanford Graduate School of Business and his A.B. in Economics with Honours from Harvard University.